优化肿瘤PD-L1表达的免疫PET显像:89Zr标记抗PD-L1抗体形式的药代动力学、生物分布和剂量学比较
该研究在荷人非小细胞肺癌异种移植瘤的裸鼠中,比较了三种源于抗PD-L1 IgG1 C4的89Zr标记放射性配体的药代动力学、生物分布和剂量学。结果显示三种配体均能特异性靶向PD-L1阳性肿瘤,Fab C4和双突变IgG C4较完整IgG C4清除更快、更早达到最大肿瘤/肌肉比,剂量学估算提示器官吸收剂量可耐受重复临床PET显像。
要点
- 89Zr-Fab C4在注射后4小时达最大肿瘤/肌肉比约6,早于双突变IgG C4的24小时和完整IgG C4的48小时。
- 89Zr-IgG C4(H310A/H435Q)最大肿瘤/肌肉比约9,89Zr-IgG C4约8,均高于Fab C4的约6。
- 三种配体在PD-L1阳性肿瘤明显聚集,而在PD-L1阴性或阻断的PD-L1阳性肿瘤中不明显,证实PD-L1特异性靶向。
核心结论
- 该研究凸显了在临床前模型中设计具有更短药代动力学的放射性配体用于PD-L1免疫PET显像的潜力,并鼓励此类放射性配体的进一步临床转化。
研究设计与样本
- 在荷皮下人非小细胞肺癌异种移植瘤(PD-L1阳性H1975模型或PD-L1阴性A549模型)的裸鼠中,通过纵向PET/CT显像比较三种89Zr标记C4配体的药代动力学、生物分布和剂量学。
主要发现
- C4放射性配体在PD-L1阳性肿瘤中大量聚集,而在PD-L1阴性肿瘤或阻断的PD-L1阳性肿瘤中不明显。
- 89Zr-Fab C4和89Zr-IgG C4(H310A/H435Q)较89Zr-IgG C4快速清除。
- 最大肿瘤/肌肉比:89Zr-Fab C4在注射后4小时约6,89Zr-IgG C4(H310A/H435Q)在注射后24小时约9,89Zr-IgG C4在注射后48小时约8。
- 非肿瘤组织本底活性低,但89Zr-Fab C4肾脏滞留高,89Zr-IgG C4(H310A/H435Q)肝脏蓄积持续,均较89Zr-IgG C4明显。
- 剂量学估算提示C4放射性配体可产生可耐受重复临床PET显像研究的器官吸收剂量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PET imaging of programmed cell death ligand 1 (PD-L1) may help to noninvasively predict and monitor responses to anti-programmed cell death 1/anti-PD-L1 immunotherapies. In this study, we compared the imaging characteristics of 3 radioligands derived from the anti-PD-L1 IgG1 complement 4 (C4). In addition to the IgG C4, we produced a fragment antigen-binding (Fab) C4, as well as a double-mutant IgG C4 (H310A/H435Q) with minimal affinity for the murine neonatal Fc receptor. Methods: The pharmacokinetics, biodistribution, and dosimetry of the 3 89Zr-labeled C4 ligands were compared by longitudinal PET/CT imaging in nude mice bearing subcutaneous human non-small cell lung cancer xenografts with positive (H1975 model) or negative (A549 model) endogenous PD-L1 expression. Results: The C4 radioligands substantially accumulated in PD-L1-positive tumors but not in PD-L1-negative tumors or in blocked PD-L1-positive tumors, confirming their PD-L1-specific tumor targeting. 89Zr-Fab C4 and 89Zr-IgG C4 (H310A/H435Q) were rapidly eliminated compared with 89Zr-IgG C4. Consequently, maximal tumor-to-muscle ratios were obtained earlier, at 4 h after injection for 89Zr-Fab C4 (ratio, ∼6) and 24 h after injection for 89Zr-IgG C4 (H310A/H435Q) (ratio, ∼9), versus 48 h after injection for 89Zr-IgG C4 (ratio, ∼8). Background activity in nontumor tissues was low, except for high kidney retention of 89Zr-Fab C4 and persistent liver accumulation of 89Zr-IgG C4 (H310A/H435Q) compared with 89Zr-IgG C4. Dosimetry estimates suggested that the C4 radioligands would yield organ-absorbed doses tolerable for repeated clinical PET imaging studies. Conclusion: This study highlights the potential of designing radioligands with shorter pharmacokinetics for PD-L1 immuno-PET imaging in a preclinical model and encourages further clinical translation of such radioligands.
引用
- Bouleau A, Nozach H, Dubois S, et al. Optimizing Immuno-PET Imaging of Tumor PD-L1 Expression: Pharmacokinetic, Biodistribution, and Dosimetric Comparisons of 89Zr-Labeled Anti-PD-L1 Antibody Formats. J Nucl Med. 2021. PMID: 34933891. doi:10.2967/jnumed.121.262967
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。